Interesting.... found Peter Kolchinsky as one of the Authors next to Hyerun Choe --- and he runs one hedge fund that digs deep into the finest of all small biotech stocks and for a virologist from Harvard to not know about Bavituximab and PS targeting is ... how shall I say it: IMPOSSIBLE. I'd say Peregrine is one of RA Capital top picks at this time and if its not.... maybe they will soon change their mind.
Farzan M, Mirzakov T, Kolchinsky P, Wyatt R, Cayabyab M, Gerard NP, Gerard C, Sodroski J, Choe H. Tyrosine Sulfation of N-terminal CCR5 facilitates HIV-1 Entry. Cell. 1999 Mar;96(5):667-76.
Small undiscovered biotech stock = Peregrine Pharmaceuticals .... not for long though!
imagine......many here owning a stock that the Kolchinsky's of the world spent over a hundred thousand dollars in IVY League education and the most respected field of virology and here some of us are that we only had to read some articles of AF to lead us the way into Peregrine! : )